AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

532.601

+6.8361.30%

Number of Gainers:12

Number of Losers:16

Number of Flat:17

PE:- -

High:534.260

Open:526.846

Low:522.056

Close:525.765

Volume:96.27M

Turnover:167.42M

Market Cap:72.74B

Float Cap:69.92B

Loading ...

How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design

Simply Wall St.

Carlisle Companies Q1 Margin Pullback Tests Long Term Expansion Thesis

Simply Wall St.

Hexcel (HXL) Q1 EPS Swings Test Bullish Earnings Growth Narrative

Simply Wall St.

Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading

MT Newswires Live

NewMarket (NEU) Margin Decline Challenges Bullish Narratives After Strong Q1 EPS

Simply Wall St.

Clinuvel plans Phase III CUV107 vitiligo trial of Scenesse plus NB-UVB vs NB-UVB

BUZZ-Medical Developments International soars on robust quarterly revenue

Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives

Simply Wall St.

BRIEF-Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo Study

BRIEF-Medical Developments International Posts Qtrly Group Revenue A$10.5 Million

Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency

MT Newswires Live

Medical Developments International Ltd - Qtrly Group Revenue a$10.5 Mln

THOMSON REUTERS

Medical Developments International - in FY26, Seasonally Softer Demand in Respiratory Segment Expected to Result Lower Earnings in H2 VS H1

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Cuv107 Study to Commence in 2H 2026

THOMSON REUTERS

Clinuvel Pharmaceuticals Ltd - Receives Final Ema Scientific Advice for Pivotal Phase Iii Vitiligo Study

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership April 2026

Simply Wall St.

Did Hexcel's (HXL) Q1 Beat and Reaffirmed Outlook Just Reset Its Aerospace Margin Story?

Simply Wall St.

Eurazeo unit Kurma Partners closes Biofund IV at EUR 215 million

Australian shares close at two-week low on oil price concerns; Santos jumps over 3%

BUZZ-Australia's CSL hits 9-year low after US scraps mandatory flu vaccines for military

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":532.60126,"timestamp":1777010399865,"preClose":525.7653,"halted":0,"volume":96274305,"delay":0,"changeRate":0.013002,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":6.835938,"latestTime":"04-24 16:00:00 AEST","open":526.8464,"high":534.26025,"low":522.05597,"amount":167424635,"amplitude":0.023212,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1777248000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1776988800000,1777010400000]],"turnoverRate":0.003746,"increases":11,"decrements":16,"flats":16,"marketCap":72741471337.75,"floatMarketCap":69916121383.8125},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":534.26025,"amplitude":0.023212,"preClose":525.7653,"low":522.05597,"latestPrice":532.60126,"volume":96274305,"delay":0,"open":526.8464,"prevYearClose":644.3692,"prevWeekClose":555.02,"prevMonthClose":565.064,"prevQuarterClose":565.064,"fiveDayClose":555.02,"twentyDayClose":563.662,"sixtyDayClose":668.222,"secType":"PLATE","market":"AU","turnoverRate":0.003746,"marketCap":72741471337.75,"floatMarketCap":69916121383.8125,"timestamp":1777010399865,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":12,"down":16,"flat":17},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630980518","title":"How Investors Are Reacting To Clinuvel Pharmaceuticals (ASX:CUV) EMA Guidance On SCENESSE Vitiligo Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2630980518","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630980518?lang=en_us&edition=fundamental","pubTime":"2026-04-25 20:10","pubTimestamp":1777119025,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals recently reported that the European Medicines Agency issued final scientific advice on its planned pivotal Phase III CUV107 trial, outlining how SCENESSE (afamelanotide) will be evaluated as a systemic treatment for non-segmental vitiligo in adults and adolescents.\nThe regulator’s “totality of evidence” approach, with T-VASI50 as the primary endpoint and strong emphasis on patient-reported and photographic outcomes, underscores both the complexity and patient-centric...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cuv/clinuvel-pharmaceuticals-shares/news/how-investors-are-reacting-to-clinuvel-pharmaceuticals-asxcu-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AGIX","BK4587","ISBC","CUV.AU","BK7508","AIPO","BK4023","AI","CHAT","BK4081","BK7067","ARTY","AIYY","BK4543","BK4211","EMA","BK4585","BK4551","BK4528","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630874424","title":"Carlisle Companies Q1 Margin Pullback Tests Long Term Expansion Thesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2630874424","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630874424?lang=en_us&edition=fundamental","pubTime":"2026-04-25 13:12","pubTimestamp":1777093945,"startTime":"0","endTime":"0","summary":"Carlisle Companies (CSL) opened 2026 with Q1 revenue of US$1,052.1 million and basic EPS of US$3.13, setting the tone for how the rest of the year might shape up for margin focused investors. Over recent quarters the company has seen revenue move from US$1,095.8 million and EPS of US$3.16 in Q1 2025 to a peak of US$1,449.5 million with EPS of US$5.93 in Q2 2025, before stepping down to US$1,052.1 million and EPS of US$3.13 in the latest quarter as attention shifts firmly to how consistently...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3061000-choice1-main-header/1585186603448"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-q1-margin-pullback-tests-long-term-expans","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-csl/carlisle-companies/news/carlisle-companies-q1-margin-pullback-tests-long-term-expans","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7508","BK4086","LU1169589451.USD","SG9999004303.SGD","BK7501","CSL","CSL.AU","BK7511","LU1169590202.USD","SGXZ23171101.USD","LU0728928796.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630878521","title":"Hexcel (HXL) Q1 EPS Swings Test Bullish Earnings Growth Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2630878521","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630878521?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:07","pubTimestamp":1777064821,"startTime":"0","endTime":"0","summary":"Hexcel (HXL) opened Q1 2026 with revenue of US$501.5 million and basic EPS of US$0.49, setting the tone for how investors are reading the new earnings season. The company has seen quarterly revenue range from US$456.5 million in Q1 2025 to US$491.3 million in Q4 2025, while basic EPS moved between US$0.17 in Q2 2025 and US$0.60 in Q4 2025. This gives a clear view of how the top and bottom lines have tracked into this latest print. With that backdrop, the key question now is whether current...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-q1-eps-swings-test-bullish-earnings-growth-narrat","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/hexcel-hxl-q1-eps-swings-test-bullish-earnings-growth-narrat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BLSG","BK4112","BK7067","LU0240877869.USD","BK4187","LU0205193047.USD","LU0240878834.USD","HXL","LU0053671581.USD","BLSX","LU0205194284.USD","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629828100","title":"Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2629828100","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629828100?lang=en_us&edition=fundamental","pubTime":"2026-04-24 22:48","pubTimestamp":1777042080,"startTime":"0","endTime":"0","summary":"Asian equities traded in the US as American depositary receipts were tracking higher Friday morning, rising 0.72% to 2,771.65 on the S&P Asia 50 ADR Index, which has fallen more than 2.5% for the week so far.From North Asia, the gainers were led by semiconductor firm ASE Technology  and internet and data center services provider VNET Group , which climbed 6.8% and 4.1% respectively. They were followed by computer hardware maker Canaan , which advanced 2.5%.The decliners from North Asia were led by LexinFintech  and Four Seasons Education , which shed 9.3% and 8.9% respectively. They were followed by financial firm Nomura  and 51Talk Online Education Group , which fell 5.6% and 4.9% respectively.From South Asia, the gainers were led by tech conglomerate Sea , which rose 1.2%, followed by pharmaceutical company Dr. Reddy's Laboratories  and lender HDFC Bank , which were up 0.7% and 0.2% respectively.The decliners from South Asia were led by telecommunications operator Telekomunikasi Indo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RDY","LU0890818403.SGD","BK7095","LU2152927971.USD","LU1267930656.SGD","LU1105468828.SGD","LU0536402901.SGD","SG9999014013.SGD","LU0823038988.USD","LU0251143029.SGD","SG9999004360.SGD","LU0345776255.USD","LU0831103253.SGD","COE","LU2226246903.HKD","SG9999002406.SGD","IE00B0JY6M65.USD","LU0499858602.USD","LU1791710582.SGD","LU0197773673.USD","SG9999004220.SGD","AIA","LU0048575426.USD","LU0868486357.SGD","SG9999001135.SGD","BK4533","IE00B3M56506.USD","SG9999006266.SGD","LU0231203729.USD","HDB","LU0572939691.SGD","LU2360107671.USD","SG9999014005.SGD","LU0456842615.SGD","LU0287143357.SGD","LU0251143458.SGD","LU0175139822.USD","LU0431992006.USD","BK4207","LU1235295612.USD","LU0261945553.USD","LU1102505762.USD","LU1804176565.USD","LU0348788117.USD","SG9999002604.SGD","LU1282648689.USD","IE0034224299.USD","LU1854104046.USD","BK7039","LU0181495838.USD","BK4554","LU1046422090.SGD","BK4532","BK4585","CAN","BK4543","LU0516423174.USD","LU1861217088.USD","NMR","BK4166","BK4600","BK4506","LU0516422366.SGD","BK7502","LU1102505929.USD","LU2238330802.EUR","LU2125910500.SGD","LU0441851309.USD","BK4107","BK4588","FEDU","SG9999005177.SGD","LU0197773160.USD","LU0261950470.USD","IBN","LU1048588211.SGD","TLK","SG9999013460.SGD","LU0072462343.USD","LU0307460401.USD","LU0898667661.SGD","LU2125910849.SGD","LU1770036033.HKD","IE0001KFT4U8.USD","BK4127","BK4503","BK4579","IE0031814969.USD","BK4116","LU2065171311.SGD","BK4523","LU1481012133.USD","BK4134","SG9999014039.USD","LU0066902890.USD","LU0589944569.HKD","SG9999002620.SGD","LU2663582299.SGD","BK4117","LU0828237940.HKD","SG9999014484.SGD","LU0791590937.USD","BK7016","LU2045819591.USD","BK7096","LU0737861269.HKD","LU1791710400.SGD","LU0823039010.USD","LU0333810181.USD","BK4526","LU0531971678.HKD","LU0918141705.HKD","LU0049112450.USD","BK4595","SG9999013486.USD","LU0143863784.USD","LU1868837722.USD","LU2087589342.USD","BK4220","LU0289960550.SGD","LU2008162690.USD","LU2543165471.USD","BK4581","LU0348816934.USD","LU0708995666.HKD","BK4170","LU0630378429.USD","LU1861220207.SGD","LU0210637038.USD","LU0390134368.USD","LU0197229882.USD","LU1048596156.SGD","LU0164881194.USD","LU2065171402.SGD","LX","BK4204","LU0918141887.USD","BK4552","BK7506","LU2065169927.USD","BK4551","LU1242518931.SGD","LU1868838027.USD","LU1839390173.USD","INFY","BK4085","LU0248272758.USD","LU1366334651.USD","SG9999002414.USD","BK4548","SGXZ58947870.SGD","BK4115","BK4557","BK4535","LU0516422952.EUR","LU0348814723.USD","LU1508157978.USD","IE00B7N09G41.SGD","LU1868837565.USD","LU2265009873.SGD","ASX","LU0791591158.USD","LU0532188223.SGD","LU0348744763.USD","BK7508","IE00BYTNYM70.SGD","LU0630378692.HKD","LU0264606111.USD","LU2279701549.SGD","LU1805238398.USD","LU0528227936.USD","SG9999013478.USD","LU0345775950.USD","LU0516423091.SGD","LU0516422440.USD","LU0541502299.USD","BK4596","LU0143863198.USD","LU0541501648.USD","BK4141","LU0979878070.USD","LU1242518857.USD","BK4607","SG9999002679.SGD","SG9999014492.USD","LU0499858438.USD","LU1366334578.USD","BK4007","LU0797268264.HKD","LU2177674079.SGD","LU0264410563.USD","BK4566","LU0821914370.USD","LU2065170008.USD","BK4531","LU0862451753.SGD","LU0572940350.SGD","SE","IE00BD6J9T35.USD","LU1323998911.USD","LU1854103824.USD","SG9999014021.USD","LU0048573645.USD","VNET"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629817942","title":"NewMarket (NEU) Margin Decline Challenges Bullish Narratives After Strong Q1 EPS","url":"https://stock-news.laohu8.com/highlight/detail?id=2629817942","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629817942?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:13","pubTimestamp":1777021991,"startTime":"0","endTime":"0","summary":"NewMarket (NEU) opened 2026 with Q1 revenue of US$669.7 million and basic EPS of US$12.62, setting the tone for how the year might shape up against its recent track record. Over the past year, the company has seen trailing twelve month revenue sit at about US$2.7 billion and basic EPS at US$43.77, giving investors a clearer view of the earnings power behind the latest quarterly print. With a trailing net profit margin of 15.2% compared with last year’s 17.2%, the story this quarter is focused...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-bullish-narratives-a","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/newmarket-neu-margin-decline-challenges-bullish-narratives-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7096","BK4109","BLSG","BLSX","BK4112","NEU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629689980","title":"Clinuvel plans Phase III CUV107 vitiligo trial of Scenesse plus NB-UVB vs NB-UVB","url":"https://stock-news.laohu8.com/highlight/detail?id=2629689980","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629689980?lang=en_us&edition=fundamental","pubTime":"2026-04-24 11:46","pubTimestamp":1777002368,"startTime":"0","endTime":"0","summary":"Clinuvel received final European Medicines Agency scientific advice on design of pivotal Phase III CUV107 study testing SCENESSE as systemic treatment for non-segmental vitiligo.Trial results have not been presented; study is slated to start in 2H 2026.CUV107 will compare SCENESSE used with narrowband UVB therapy versus narrowband UVB alone in 300 patients.EMA signaled it will weigh overall clinical package, including patient-reported assessments, when judging whether repigmentation benefits support marketing authorization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clinuvel Pharmaceuticals Limited published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contai","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL59dwNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","CUV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629896679","title":"BUZZ-Medical Developments International soars on robust quarterly  revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2629896679","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629896679?lang=en_us&edition=fundamental","pubTime":"2026-04-24 11:23","pubTimestamp":1777001022,"startTime":"0","endTime":"0","summary":"BUZZ-Medical Developments International soars on robust quarterly revenue** Shares of Australia's Medical Developments International MVP.AX rise as much as 35.1% to A$0.52, their highest level since January 22** On track to log its steepest intraday pct rise since April 29, 2025** The pharmaceuticals company posts third quarter revenue of A$10.5 million , up A$1.6 million on pcp** About 803,000 shares change hands, 7.8 times the 30-day avg** Down 12.6% YTD, including the session's moves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nL6N41707E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","MVP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629750895","title":"Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2629750895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629750895?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:19","pubTimestamp":1776997156,"startTime":"0","endTime":"0","summary":"Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK7508","MSB","BK4006","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629898305","title":"BRIEF-Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629898305","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629898305?lang=en_us&edition=fundamental","pubTime":"2026-04-24 09:29","pubTimestamp":1776994152,"startTime":"0","endTime":"0","summary":"BRIEF-Clinuvel Pharmaceuticals Receives Final EMA Scientific Advice For Pivotal Phase III Vitiligo StudyApril 24  - Clinuvel Pharmaceuticals Ltd CUV.AX:RECEIVES FINAL EMA SCIENTIFIC ADVICE FOR PIVOTAL PHASE III VITILIGO STUDYCUV107 STUDY TO COMMENCE IN 2H 2026Further company coverage: CUV.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nFWN4161BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629983138","title":"BRIEF-Medical Developments International Posts Qtrly Group Revenue A$10.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629983138","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629983138?lang=en_us&edition=fundamental","pubTime":"2026-04-24 09:25","pubTimestamp":1776993952,"startTime":"0","endTime":"0","summary":"BRIEF-Medical Developments International Posts Qtrly Group Revenue A$10.5 MillionApril 24  - Medical Developments International Ltd MVP.AX:QTRLY GROUP REVENUE A$10.5 MILLIONIN FY26, SEASONALLY SOFTER DEMAND IN RESPIRATORY SEGMENT EXPECTED TO RESULT LOWER EARNINGS IN H2 VERSUS H1Further company coverage: MVP.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nFWN41615A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","MVP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629862958","title":"Clinuvel Pharmaceuticals Set for Phase 3 Vitiligo Study After Final Advice From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2629862958","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629862958?lang=en_us&edition=fundamental","pubTime":"2026-04-24 08:10","pubTimestamp":1776989406,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals (ASX:CUV) said the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a \"totality of evidence\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","BK7129","EMA.AU","MDCO","CUV.AU","BK4081","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629861795","title":"Medical Developments International Ltd -  Qtrly Group Revenue a$10.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2629861795","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629861795?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:59","pubTimestamp":1776985167,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN41615A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","MVP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629686108","title":"Medical Developments International -  in FY26, Seasonally Softer Demand in Respiratory Segment Expected to Result Lower Earnings in H2 VS H1","url":"https://stock-news.laohu8.com/highlight/detail?id=2629686108","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629686108?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:59","pubTimestamp":1776985167,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN41615A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","MVP.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629768861","title":"Clinuvel Pharmaceuticals Ltd -  Cuv107 Study to Commence in 2H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629768861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629768861?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:56","pubTimestamp":1776985001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4161BB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629617518","title":"Clinuvel Pharmaceuticals Ltd - Receives Final Ema Scientific Advice for Pivotal Phase Iii Vitiligo Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2629617518","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629617518?lang=en_us&edition=fundamental","pubTime":"2026-04-24 06:56","pubTimestamp":1776985001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nFWN4161BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629502869","title":"ASX Growth Companies With High Insider Ownership April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629502869","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629502869?lang=en_us&edition=fundamental","pubTime":"2026-04-24 03:08","pubTimestamp":1776971318,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a complex landscape marked by geopolitical tensions and fluctuating commodity prices, investors are keeping a close eye on growth companies with high insider ownership. In such an environment, stocks with significant insider stakes can be appealing due to the potential alignment of interests between company leaders and shareholders, offering a sense of confidence amidst global uncertainties.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2052000-choice1-main-header/1585186836557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-companies-with-high-insider-ownership-april-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ltr/liontown-shares/news/asx-growth-companies-with-high-insider-ownership-april-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7143","IMA.AU","BK7096","BK7095","BK7501","SKS.AU","BK7504","LTR.AU","CUV.AU","CBO.AU","XAO.AU","MAU.AU","TTT.AU","XKO.AU","FRS.AU","BK7104","BK7110","BK7508","BK7016","SPL.AU","TOR.AU","BK7141","BK7067","AR1.AU","ASG.AU","BK7023","BK7036","XJO.AU","AV1.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629285277","title":"Did Hexcel's (HXL) Q1 Beat and Reaffirmed Outlook Just Reset Its Aerospace Margin Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629285277","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629285277?lang=en_us&edition=fundamental","pubTime":"2026-04-24 02:10","pubTimestamp":1776967801,"startTime":"0","endTime":"0","summary":"Hexcel Corporation recently reported first-quarter 2026 results, with sales of US$501.5 million and net income of US$37.2 million, and its Board declared a regular quarterly cash dividend of US$0.18 per share payable on May 11, 2026.\nThe quarter’s earnings and revenue exceeded analyst expectations across both Composite Materials and Engineered Products, while management reaffirmed full-year revenue and adjusted EPS guidance, signalling confidence in operational execution.\nWe’ll now assess...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/did-hexcels-hxl-q1-beat-and-reaffirmed-outlook-just-reset-it","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/did-hexcels-hxl-q1-beat-and-reaffirmed-outlook-just-reset-it","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","LU0205194284.USD","LU0205193047.USD","LU0240878834.USD","HXL","LU0053671581.USD","BK7067","HXL.AU","LU0240877869.USD","BK4187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629383142","title":"Eurazeo unit Kurma Partners closes Biofund IV at EUR 215 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2629383142","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629383142?lang=en_us&edition=fundamental","pubTime":"2026-04-23 20:34","pubTimestamp":1776947692,"startTime":"0","endTime":"0","summary":"Kurma Partners, Eurazeo group company, closed Biofund IV at EUR 215 million.Fund size rose nearly 35% from EUR 160 million for Biofund III.Cornerstone investors include CSL, European Investment Fund, Bpifrance.Kurma Partners total assets under management reached EUR 1 billion.Biofund IV completed 11 investments, targets about 20.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurazeo SE published the original content used to generate this news brief on April 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL6Dz3c5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CSL.AU","BK7511","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629000490","title":"Australian shares close at two-week low on oil price concerns; Santos jumps over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629000490","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629000490?lang=en_us&edition=fundamental","pubTime":"2026-04-23 15:04","pubTimestamp":1776927869,"startTime":"0","endTime":"0","summary":"Australian shares close at two-week low on oil price concerns; Santos jumps over 3%Updates to closeMiners down 1%, banks fall 0.7%Santos gains 3.6% NZ 50 drops to three-week lowBy Keshav SinghChundawat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL4N4160GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7142","LU0788109121.HKD","LU0955669360.SGD","LU0831103253.SGD","LU0955623706.USD","LU0971552830.HKD","BK7511","FMG.AU","LU1302929846.USD","LU0572940350.SGD","LU0898667661.SGD","LU0345777659.USD","LU1046248800.SGD","RIO.UK","LU0330918003.SGD","LU0572939691.SGD","LU0075056555.USD","LU0505663152.USD","LU1309081286.SGD","STO.AU","LU0345777147.USD","LU0264606111.USD","IE00BWDBJ516.SGD","BK5111","IE00B3M56506.USD","LU0612318385.USD","LU1064927863.SGD","BK7067","BK7501","LU2463526074.USD","LU1481600234.SGD","BK7508","LU0971552673.USD","LU0011963245.USD","LU0345780950.USD","LU0630314457.HKD","LU1487256676.USD","BK7129","CSL.AU","LU0654597011.USD","LU1130305938.SGD","LU0955648018.USD","LU0456854461.SGD","LU0171293334.USD","LU1078025761.USD","SG9999002521.SGD","IE00BQJZX424.USD","WDS.AU","LU1430597077.USD","SG9999001143.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629019780","title":"BUZZ-Australia's CSL hits 9-year low after US scraps mandatory flu vaccines for military","url":"https://stock-news.laohu8.com/highlight/detail?id=2629019780","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629019780?lang=en_us&edition=fundamental","pubTime":"2026-04-23 13:23","pubTimestamp":1776921818,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL hits 9-year low after US scraps mandatory flu vaccines for military** Shares of CSL Ltd CSL.AX fall as much as 1% to A$127.85, its lowest since Aug 31, 2017** Stock extends previous session's near-6% drop, on track for third straight day of losses** U.S. defense department said on Tuesday that military personnel would no longer be mandated to receive the flu vaccine** Biotech firm is heavily exposed to the U.S., its largest revenue source** Firm's vaccines business, including influenza shots supplied through unit CSL Seqirus, is one of its most profitable divisions** YTD, stock down 25.4%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL6N4160BL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","CSL.AU","BK7501","BK7511"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":128,"code":"91000000","status":"200"}]}}